(19)
(11) EP 2 354 228 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A3)

(48) Corrigendum issued on:
14.03.2012 Bulletin 2012/11

(88) Date of publication A3:
02.11.2011 Bulletin 2011/44

(43) Date of publication:
10.08.2011 Bulletin 2011/32

(21) Application number: 11154637.0

(22) Date of filing: 24.10.2005
(51) International Patent Classification (IPC): 
C12N 15/09(2006.01)
G01N 27/62(2006.01)
 C12Q 1/68(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 28.10.2004 JP 2004314160

(62) Application number of the earlier application in accordance with Art. 76 EPC:
05795708.6 / 1813673

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
Chiyoda-ku Tokyo 101-8535 (JP)

(72) Inventors:
  • Seki, Toyokazu
    Tokushima 7710130 (JP)
  • Shiratsuchi, Takayuki
    Eastchester, NY 10709 (US)
  • Ogawa, Osamu
    Kyoto 6068507 (JP)
  • Naito, Seiji
    Fukuoka 8128582 (JP)
  • Tsukamoto, Taiji
    Hokkaido 0608556 (JP)
  • Toma, Hiroshi
    Tokyo 1628666 (JP)
  • Hirao, Yoshihiko
    Nara 6348521 (JP)
  • Kagawa, Susumu
    Tokushima 7708503 (JP)
  • Nose, Yoshiaki
    Fukuoka 8128582 (JP)
  • Nakamura, Tsuyoshi
    Nagasaki 8128521 (JP)

(74) Representative: HOFFMANN EITLE 
Patent- und Rechtsanwälte Arabellastraße 4
81925 München
81925 München (DE)

   


(54) Identification marker responsive to interferon therapy for renal cell cancer


(57) The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.